Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium Meeting Abstract

  

Authors:	Wiebe, L.; Kasza, K. E.; Maki, R. G.; D'Adamo, D. R.; Chow, W. A.; Wade, J. L.; Agamah, E.; Stadler, W. M.; Vokes, E. E.; Kindler, H. L.
Abstract Title:	Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium
Meeting Title:	44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	26
Issue:	15 Suppl.
Meeting Dates:	2008 May 30-Jun 3
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2008-05-20
Start Page:	553s
Language:	English
ACCESSION:	WOS:000208457403746
DOI:	10.1200/jco.2008.26.15_suppl.10502
PROVIDER:	wos
Notes:	Meeting Abstract: 10502 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/129883